MarketPulse

LDL cholesterol

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CRISPR Therapeutics' Gene-Editing Pipeline Targets $100B+ Cardiovascular Market

CRISPR Therapeutics advances promising pipeline candidates CTX310 and CTX320 targeting cardiovascular disease, though company remains unprofitable with minimal revenue.
CRSPgene therapyType 1 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Editas Medicine Slashes Q4 Losses While Advancing CRISPR Therapy Toward Human Trials

Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.
BMYCELGrEDITclinical trialCRISPR